Zosano Pharma Corporation (ZSAN) Announces Earnings Results, Misses Estimates By $0.02 EPS
Zosano Pharma Corporation (NASDAQ:ZSAN) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.02, Bloomberg Earnings reports. During the same period in the prior year, the company earned ($0.54) EPS.
Shares of Zosano Pharma Corporation (NASDAQ:ZSAN) traded down 5.05% during trading on Thursday, hitting $0.94. 609,833 shares of the company’s stock were exchanged. Zosano Pharma Corporation has a one year low of $0.45 and a one year high of $3.54. The stock’s market cap is $36.85 million. The firm has a 50-day moving average price of $1.30 and a 200-day moving average price of $1.58.
Separately, ValuEngine raised shares of Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $2.58.
TRADEMARK VIOLATION WARNING: “Zosano Pharma Corporation (ZSAN) Announces Earnings Results, Misses Estimates By $0.02 EPS” was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/10/zosano-pharma-corporation-zsan-announces-earnings-results-misses-estimates-by-0-02-eps.html.
In other news, CFO Georgia Erbez acquired 68,000 shares of Zosano Pharma Corporation stock in a transaction that occurred on Thursday, May 25th. The stock was purchased at an average price of $1.32 per share, for a total transaction of $89,760.00. Following the purchase, the chief financial officer now directly owns 115,750 shares in the company, valued at approximately $152,790. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Peter Walker acquired 73,716 shares of Zosano Pharma Corporation stock in a transaction that occurred on Thursday, May 25th. The shares were purchased at an average price of $1.36 per share, with a total value of $100,253.76. Following the purchase, the chief executive officer now owns 169,344 shares in the company, valued at $230,307.84. The disclosure for this purchase can be found here. Insiders own 2.95% of the company’s stock.
Zosano Pharma Corporation Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.